Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens
NCT06554327 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 265
Last updated 2025-06-17
Summary
Ventilator-associated pneumonia (VAP) remains one of the main nosocomial infections acquired in the intensive care unit (ICU). VAP is pneumonia occurring 48 hours after intubation. Today, bronchoalveolar lavage (BAL) is used for microbiological diagnosis, with bacterial culture and antibiotic susceptibility results within 48 to 72 hours. Multiplex PCR can detect DNA of a number of bacteriae, as well as the presence of resistance genes. However, its clinical value in the ICU remains to be demonstrated. We think that the use of multiplex PCR with a panel adapted to the microbiology of VAP, could be an interesting method for clinicians in ICU.
Conditions
- Ventilator Associated Pneumonia
Interventions
- DEVICE
-
Multiplex PCR
In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
Sponsors & Collaborators
-
CHU de Reims
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-06
- Primary Completion
- 2026-09-06
- Completion
- 2026-10-06
Countries
- France
Study Locations
More Related Trials
-
Microbiological Profile of VAP Patients in Respiratory ICU
NCT05738928 ·Status: UNKNOWN
-
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
NCT07052604 ·Status: RECRUITING
-
Bilateral Bronchoalveolar Lavage in Ventilator-associated Pneumonia
NCT02542553 ·Status: COMPLETED ·Phase: NA
-
Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia
NCT05464680 ·Status: COMPLETED ·Phase: NA
-
Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
NCT01042353 ·Status: COMPLETED ·Phase: PHASE4
-
Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection
NCT03382548 ·Status: COMPLETED ·Phase: PHASE3
-
Direct Molecular Characterization of Bacteria From ICU and From the REHAB
NCT03475472 ·Status: COMPLETED
-
Impact of Direct Antimicrobial Susceptibility Testing on Respiratory Sample of Intensive Care Patient With Suspected VAP
NCT02897466 ·Status: UNKNOWN ·Phase: NA
-
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
NCT01875692 ·Status: COMPLETED
-
Impact of Antibio Prophylaxis on Occurence of Ventilator Associated Pneumonia in Trauma Patients
NCT07059039 ·Status: COMPLETED
-
Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care
NCT05124977 ·Status: RECRUITING ·Phase: NA
-
Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia
NCT01770015 ·Status: COMPLETED ·Phase: NA
-
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
NCT03303937 ·Status: COMPLETED
-
Predictive Factors of Good Pulmonary Penetration of Antibiotics : AntiBiotics Dosage in Broncho-Alveolar Lavage
NCT03927079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP)
NCT02077920 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia
NCT03149640 ·Status: COMPLETED ·Phase: PHASE3
-
Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP)
NCT05205525 ·Status: COMPLETED
-
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
NCT03752476 ·Status: UNKNOWN
-
Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients
NCT06379139 ·Status: RECRUITING
-
Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU
NCT05741424 ·Status: COMPLETED ·Phase: NA
-
Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit
NCT04355481 ·Status: UNKNOWN
-
Ventilation Associated Pneumonia and Covid-19
NCT05089968 ·Status: COMPLETED
-
Airway Microbiome Changes After Artificial Airway Exchange in Critically-ill Pediatric Patients.
NCT06201130 ·Status: RECRUITING
-
Early Antibiotics After Aspiration in ICU Patients
NCT05079620 ·Status: TERMINATED ·Phase: PHASE4
-
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia
NCT02478710 ·Status: TERMINATED ·Phase: PHASE4